EBITDA grew 11% and sales rose 6% year-to-date, with margin improvements and accretive acquisitions. Free cash flow declined due to IPO costs, while leverage remained stable and the acquisition pipeline is more active in 2025.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.